|Articles|November 16, 2003
The Anti-VEGF Aptamer Approach: The Macugen Collaborative Trial
Recent results of clinical trials of the anti-VEGF aptamer Macugen (pegaptanibsodium are extremely promising for patients with choroidal neovascularization,said Carmen Puliafito, MD, MBNA, chairman of the Bascom Palmer Eye Institute,Miami.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Metformin use associated with reduced incidence of intermediate AMD
2
MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
3
Looking back at the 2025 EnVision Summit
4
Last year in glaucoma at EnVision Summit 2025
5
























